还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

! c1 _3 q5 E: S* D                               
登录/注册后可看大图

6 }2 {  X0 U6 K" N( g请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
" v2 L; w% C8 q" {
$ T3 P$ G: u% m% w7 W; Y# `& Q
1 e' i* b1 y' A5 Y  R6 W) `: iSub-category:
Molecular Targets


5 {0 |& U8 g! w, x8 lCategory:
& k& f" C! s3 R6 [Tumor Biology
( n6 W" V  j  Z/ A  k0 G: ^2 y

Meeting:
2011 ASCO Annual Meeting
$ i/ W/ \3 L1 W7 Z- |

Session Type and Session Title:
# h  C' s) E: m$ v' W9 e/ r  iPoster Discussion Session, Tumor Biology
6 V% g0 Q/ D4 X# X' ~

, g- Q1 }4 a; z  W% P1 EAbstract No:
10517

" m3 `6 v8 B6 r: S7 \2 P8 K! i8 }9 ^
Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)
' N3 d6 ]. K0 `) E
, D! l0 ?# ~6 d
Author(s):
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China

5 ^% ]$ l+ x; L' o' `2 a- t

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.

Abstract Disclosures

Abstract:
, E: p1 {0 T2 `) }+ Q

Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

4 j0 Y$ v9 P  T$ \1 ^3 O* D: T

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

' U/ G# S9 }' {" Q, \3 t, H化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

- n; l  o2 M9 J  w                               
登录/注册后可看大图

& I& v% N4 K! V4 f* I1 i易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
# M) _5 s" x2 O9 ?1 O5 L2 VALK一个指标医院要900多 ...

# P" X2 D. \- Q2 Y- W平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
+ ?/ d6 Q, }% G
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊